2. Signaling Pathways
  3. Neuronal Signaling
  4. Glucosylceramide Synthase (GCS)
  5. Glucosylceramide Synthase (GCS) Inhibitor

Glucosylceramide Synthase (GCS) Inhibitor

Glucosylceramide Synthase (GCS) Inhibitors (5):

Cat. No. Product Name Effect Purity
  • HY-17020A
    Miglustat hydrochloride
    		Inhibitor 98.20%
    Miglustat (N-Butyldeoxynojirimycin) hydrochloride is an orally active ceramide glucosyltransferase inhibitor. Miglustat hydrochloride can be used for the research of type I gaucher disease.
  • HY-17020
    Miglustat
    		Inhibitor
    Miglustat (N-Butyldeoxynojirimycin) is an orally active ceramide glucosyltransferase inhibitor. Miglustat can be used for the research of type I gaucher disease.
  • HY-114615
    AMP-Deoxynojirimycin
    		Inhibitor
    AMP-Deoxynojirimycin (AMP-DNM) is a potent ceramide glucosyltransferase and GCase 2 inhibitor. AMP-Deoxynojirimycin also is a GlcCer biosynthesis inhibitor.
  • HY-116392E
    D-threo-PDMP
    		Inhibitor
    D-threo-PDMP is a potent glucoceramide synthase (GCS) inhibitor, which reduces the glycosphingolipids on the cell surface by inhibiting glycosylation, reduces the total length of the axon plexus and the number of axon branch points, and inhibits neurite growth.
  • HY-148786
    Nizubaglustat
    		Inhibitor
    Nizubaglustat is an inhibitor of Ceramide Glucosyltransferase or Glucosylceramide Synthase (GCS). Nizubaglustat also inhibits GBA2, involving in neuropathological lysosomal storage disorders.